Related references
Note: Only part of the references are listed.The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1
Oleg Kruglov et al.
BLOOD ADVANCES (2020)
Novel Therapeutics for Epstein-Barr Virus
Graciela Andrei et al.
MOLECULES (2019)
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors
Jonathan R. Kerr
JOURNAL OF CLINICAL PATHOLOGY (2019)
Dipyridamole as a new drug to prevent Epstein-Barr virus reactivation
Marcos P. Thome et al.
ANTIVIRAL RESEARCH (2019)
KRAB-ZFP Repressors Enforce Quiescence of Oncogenic Human Herpesviruses
Xiaofan Li et al.
JOURNAL OF VIROLOGY (2018)
PDE5 inhibition eliminates cancer stem cells via induction of PKA signaling
Saskia Klutzny et al.
CELL DEATH & DISEASE (2018)
Poly(ADP-ribose) Polymerase 1, PARP1, modifies EZH2 and inhibits EZH2 histone methyltransferase activity after DNA damage
Lisa B. Caruso et al.
Oncotarget (2018)
Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression
Xiang Zheng et al.
JOURNAL OF VIROLOGY (2018)
Contribution of the KSHV and EBV lytic cycles to tumourigenesis
Oliver Manners et al.
CURRENT OPINION IN VIROLOGY (2018)
PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide
Laurence Booth et al.
ONCOTARGET (2017)
Arsenic trioxide inhibits EBV reactivation and promotes cell death in EBV-positive lymphoma cells
Qinyan Yin et al.
VIROLOGY JOURNAL (2017)
Phosphodiesterase type 5 and cancers: progress and challenges
Ines Barone et al.
ONCOTARGET (2017)
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin
S. J. Kim et al.
ANNALS OF ONCOLOGY (2016)
Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL
Sima Rozati et al.
CLINICAL CANCER RESEARCH (2016)
Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir
Kwai Fung Hui et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis
Hongde Li et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2016)
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
Adam Petrich et al.
LEUKEMIA & LYMPHOMA (2016)
Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance
Y-L Kwong et al.
LEUKEMIA (2014)
Inhibition of Epstein-Barr Virus Lytic Cycle by an Ethyl Acetate Subfraction Separated from Polygonum cuspidatum Root and Its Major Component, Emodin
Ching-Yi Yiu et al.
MOLECULES (2014)
Modes of infection and oncogenesis by the Epstein-Barr virus
Takayuki Murata et al.
REVIEWS IN MEDICAL VIROLOGY (2014)
Regulation of the latent-lytic switch in Epstein-Barr virus
Shannon C. Kenney et al.
SEMINARS IN CANCER BIOLOGY (2014)
Bortezomib and SAHA Synergistically Induce ROS-Driven Caspase-Dependent Apoptosis of Nasopharyngeal Carcinoma and Block Replication of Epstein-Barr Virus
Kwai Fung Hui et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Epstein-Barr virus and host cell methylation: regulation of latency, replication and virus reactivation
Anne Woellmer et al.
CURRENT OPINION IN VIROLOGY (2013)
Methylation profiling of Epstein-Barr virus immediate-early gene promoters, BZLF1 and BRLF1 in tumors of epithelial, NK- and B-cell origins
Lili Li et al.
BMC CANCER (2012)
Pretreatment EBV-DNA Copy Number Is Predictive of Response and Toxicities to SMILE Chemotherapy for Extranodal NK/T-cell Lymphoma, Nasal Type
Yoshinori Ito et al.
CLINICAL CANCER RESEARCH (2012)
Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
Bertrand Coiffier et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Cellular Ataxia Telangiectasia-Mutated Kinase Promotes Epstein-Barr Virus Lytic Reactivation in Response to Multiple Different Types of Lytic Reactivation-Inducing Stimuli
Stacy R. Hagemeier et al.
JOURNAL OF VIROLOGY (2012)
Dual Roles of PARP-1 Promote Cancer Growth and Progression
Matthew J. Schiewer et al.
CANCER DISCOVERY (2012)
BZLF1 Governs CpG-Methylated Chromatin of Epstein-Barr Virus Reversing Epigenetic Repression
Anne Woellmer et al.
PLOS PATHOGENS (2012)
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study
Arnaud Jaccard et al.
BLOOD (2011)
Prospective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal type
Ritsuro Suzuki et al.
BLOOD (2011)
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Richard L. Piekarz et al.
BLOOD (2011)
A Novel KRAB Domain-containing Zinc Finger Transcription Factor ZNF431 Directly Represses Patched1 Transcription
Zhenhua He et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Phase II Study of SMILE Chemotherapy for Newly Diagnosed Stage IV, Relapsed, or Refractory Extranodal Natural Killer (NK)/T-Cell Lymphoma, Nasal Type: The NK-Cell Tumor Study Group Study
Motoko Yamaguchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PRDM1 is a tumor suppressor gene in natural killer cell malignancies
Can Kuecuek et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy
M. Javle et al.
Therapeutic Advances in Medical Oncology (2011)
ZNF552, a novel human KRAB/C2H2 zinc finger protein, inhibits AP-1-and SRE-mediated transcriptional activity
Yun Deng et al.
BMB REPORTS (2010)
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report
David Ritchie et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
TORC2, a Coactivator of cAMP-response Element-binding Protein, Promotes Epstein-Barr Virus Reactivation from Latency through Interaction with Viral BZLF1 Protein
Takayuki Murata et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
Phase II Trial of Concurrent Radiation and Weekly Cisplatin Followed by VIPD Chemotherapy in Newly Diagnosed, Stage IE to IIE, Nasal, Extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma Study
Seok Jin Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma
Hyo Song Kim et al.
LEUKEMIA & LYMPHOMA (2009)
Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model
GK Hong et al.
JOURNAL OF VIROLOGY (2005)
Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients
WY Au et al.
BLOOD (2004)
Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality
DJ Nichols et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2002)
Epstein-Barr virus infection.
JI Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
